Standard Nivolumab Dosing
Nivolumab (Opdivo) follows fixed-dose regimens based on FDA approvals, not initial patient weight or body surface area. Common schedules include:
- 240 mg every 2 weeks.
- 360 mg every 3 weeks.
- 480 mg every 4 weeks.
These apply across indications like melanoma, non-small cell lung cancer, and renal cell carcinoma.[1]
Role of Response in Dose Adjustments
Patient response does not typically trigger routine dosage changes. Dosing remains fixed unless:
- Disease progression: Treatment stops or switches; no dose increase occurs.
- Severe toxicity: Hold or discontinue based on CTCAE grade (e.g., hold for grade 2 immune-related adverse events, resume at same dose upon recovery).[1][2]
Guidelines from NCCN and ASCO emphasize monitoring radiographic response (e.g., RECIST criteria) and biomarkers like PD-L1 expression for treatment decisions, but not for altering nivolumab dose mid-course.[3]
Why Fixed Dosing Over Response-Based?
Pharmacokinetic studies show flat dosing achieves consistent exposure across body weights (45-120+ kg), simplifying administration without response-driven tweaks. Early weight-based dosing (3 mg/kg) shifted to fixed for practicality, with similar efficacy.[4]
Exceptions in Combinations
In combos like nivolumab + ipilimumab, response influences continuation (e.g., stop ipilimumab after 4 doses if stable), but nivolumab dose stays fixed.[1]
Ongoing Trials on Adaptive Dosing
Limited trials explore response-guided adjustments, such as biomarker-driven dosing in NSCLC, but none are standard. No approvals link dosage directly to response metrics like tumor burden reduction.[5]
[1]: Opdivo Prescribing Information
[2]: NCCN Guidelines: Immunotherapy
[3]: ASCO Guidelines: Checkpoint Inhibitors
[4]: Pharmacokinetics of Nivolumab
[5]: ClinicalTrials.gov Search: Nivolumab Adaptive Dosing